Small molecule · Inhibitor of SGLT2 (SLC5A2) and SGLT1 (SLC5A1) · developed by Lexicon Pharms
Sotagliflozin is a small-molecule inhibitor of SGLT2 and SGLT1. It reduces renal reabsorption of glucose and sodium in the kidneys and intestinal absorption of glucose and sodium in the gastrointestinal tract.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 12, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07211802 | Phase 3 | Type 1 Diabetes (T1D) | Not yet recruiting | LXRX |
| NCT06217302 | Phase 3 | Diabetic Nephropathies | Recruiting | LXRX |
| NCT02926937 | Phase 3 | Type 2 Diabetes Mellitus | Completed | LXRX |
| NCT02494609 | Phase 1 | Healthy | Unknown | LXRX |
| NCT02373046 | Phase 1 | Healthy | Completed | LXRX |
| NCT02300363 | Phase 1 | Healthy | Completed | LXRX |
| NCT02300350 | Phase 1 | Healthy | Completed | LXRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Diabetes Mellitus Type 1Diabetic NephropathiesHeart FailureKidney Failure, ChronicType 1 Diabetes (T1D)HealthyType 2 Diabetes Mellitus
Updated Oct 3, 2026. Something wrong or missing? Report it on the LXRX page.
See LXRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LXRX catalysts and pipeline →